GLP-1 Daily: Ozempic & Wegovy News

By GLP-1 Daily: Ozempic & Wegovy News — Lantern PodcastsNews Medicine Health & Fitness Daily News

GLP-1 Daily: Ozempic & Wegovy News episodes

October 09Lilly's Oral GLP-1 Orforglipron Clears Heart-Safety Bar in ACHIEVE-4 — October 09, 2026
Eli Lilly's once-daily oral GLP-1 orforglipron showed no excess cardiovascular risk against insulin glargine in the 2,749-patient ACHIEVE-4 trial, published in The Lancet. That clears a key regulatory hurdle, while an NEJM perspective warns that obesity drug trials aren't built to detect emerging harms.
In this episode
Step Back — With the FDA warning Empower Pharmacy over what it calls an “inordinate” number of copies of weight-loss drugs, how does the agency distinguish lawful compounding for individual patients from an impermissible copy—and what should patients ask their prescriber or pharmacy to understand which kind they’re receiving?Background sources
Will an FDA crackdown curb access to cheaper GLP-1 weight-loss drugs? Here's what to know. - CBS News — Cbsnews
FDA Warning Letter to Empower Pharmacy and What It Means for 503A Compounding Pharmacies | Buchanan Ingersoll & Rooney PC — ,
FDA Warning Letter Targets Compounded GLP-1 Products — Edgar J. Asebey, Guilherme Ferrari Faviero
FDA Warning Letter To Empower Pharmacy And What It Means For 503A Compounding Pharmacies - Healthcare - United States — Lucas Morgan
Empower, the B Vitamin, and the Word “Pretextual” — Lumalexlaw
FDA Warning Letter Questions “Significant Difference” Documentation for Compounded GLP-1s | Spakinect — Paulina Riedler, RN
Major trial confirms CVD safety of oral GLP‑1RA — The Limbic“The once-daily oral GLP-1RA orforglipron does not show any excess cardiovascular risks when compared with insulin glargine for patients with type 2 diabetes, data presented at the European Association for the Study of Diabetes 2026 meeting has shown. Highly anticipated results…”
NEJM Interview: Sarah Schmitz on protections for people enrolled in trials of investigational agents for obesity. — Exa“So trials of obesity pharmacotherapies have largely been designed with change in BMI as the primary endpoint and a goal of maximizing weight loss. So my concern is that these trials aren't built to detect the harms that have become more likely as obesity pharmacotherapy is…”
Daily TopFive for GLP-1 Daily: Ozempic & Wegovy News. Links above go to the original articles. Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected].
7 min
October 08GLP-1 Users Lost Sight in the Second Eye Sooner, Ophthalmology Study Finds as Vision-Loss Lawsuits Grow — October 08, 2026
An American Academy of Ophthalmology meeting study links GLP-1 use to faster second-eye NAION, as federal eye-injury cases climb to 247; plus Medicare Bridge paperwork gaps for cash-pay patients, pharmacists seeing more cash GLP-1 fills, the WHO's first childhood obesity guidelines, and Korea's first homegrown GLP-1 obesity drug.
In this episode
GLP-1 Drugs Linked to Faster Vision Loss in the Second Eye, New Study Finds | Newswise — American Academy of Ophthalmology (AAO
GLP-1 Drugs Linked to Faster Vision Loss in the Second Eye, New Study Finds | Newswise
# GLP-1 Drugs Linked to Faster Vision Loss in the Second Eye, New Study Finds
###### Among patients who suffered a rare optic nerve stroke in both eyes, those taking GLP-1 drugs saw the second eye affected sooner. They caution that causation hasn’t been established, only an association.
6-Oct-2026 at 9:30…
Medicare’s Missing On-Ramp For Access To GLP-1s For Weight Management | Health Affairs — T. Joseph Mattingly II
Medicare’s Missing On-Ramp For Access To GLP-1s For Weight Management | Health Affairs
# Medicare’s Missing On-Ramp For Access To GLP-1s For Weight Management
- T. Joseph Mattingly II,
- Rena M. Conti,
- and
- Sean D. Sullivan
October 7, 2026
Medicare’s GLP-1 Bridge program is off to a fast start, but gaps in prior authorization design may exclude beneficiaries who began GLP-1 therapy…
Patients increasingly bypass insurance to pay cash for GLP-1 prescriptions, pharmacists say — Bill Schiffner
Patients increasingly bypass insurance to pay cash for GLP-1 prescriptions, pharmacists say
# Patients increasingly bypass insurance to pay cash for GLP-1 prescriptions, pharmacists say
The trend reflects the rapidly evolving GLP-1 marketplace.
, and Bill Schiffner
October 7, 2026 . 10:06 AM
HIALEAH, Fla. — A growing number of patients are choosing to pay cash for GLP-1 medications…
Should kids living with obesity be on GLP-1s? New global guidance says yes — in some cases — CBC News
Should kids living with obesity be on GLP-1s? New global guidance says yes — in some cases
## Should kids living with obesity be on GLP-1s? New global guidance says yes — in some cases
New Lauren Pelley | CBC News | Posted: October 7, 2026 8:00 AM | Last Updated: Just now
World Health Organization has released its first-ever guidelines on managing childhood obesity
Image | VANCOUVER NEW…
MFDS approves Hanmi's EPPE, Korea's first homegrown GLP-1 obesity drug · Local Chorus — Local Chorus
MFDS approves Hanmi's EPPE, Korea's first homegrown GLP-1 obesity drug · Local Chorus
# MFDS approves Hanmi's EPPE, Korea's first homegrown GLP-1 obesity drug
🇰🇷 South Korea, Seoul 09:37 Health Business 8 Official updated 2 h ago first reported by 서울경제 Copy link
## In short
Korea's Ministry of Food and Drug Safety approved Hanmi Pharmaceutical's EPPE auto-injector (efpeglenatide) on Oct 7,…
Daily TopFive for GLP-1 Daily: Ozempic & Wegovy News. Links above go to the original articles. Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected].
12 min
October 07Medicare's $50 GLP-1 Bridge Leaves Out Some Sick Seniors — October 07, 2026
Medicare's $50-a-month GLP-1 Bridge pilot is denying some obese seniors who have certain diagnoses, such as severe sleep apnea. Separately, Amylyx will present Phase 3 avexitide data for post-bariatric hypoglycemia at ObesityWeek in November.
In this episode
Amylyx to Present Phase 3 LUCIDITY Data at ObesityWeek | AMLX Stock News — Stock Titan
# Amylyx to Present Phase 3 LUCIDITY Data at ObesityWeek | AMLX Stock News
Author: Amylyx Pharmaceuticals, Inc.
Published: 2026-10-06T12:00:00Z
Source: stocktitan.net
Language: en
## Story
Amylyx to Present Phase 3 LUCIDITY Data at ObesityWeek | AMLX Stock News
# Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at…
The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify | Sleep Review — Sleep Review
# The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify | Sleep Review
Author: Sree Roy
Published: 2026-10-06T18:27:06Z
Source: sleepreviewmag.com
Language: en
## Story
The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify | Sleep Review
# The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify
Oct 6, 2026 | Medicare…
Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email [email protected].
5 min
October 06Federal Plans Tie 2027 GLP-1 Coverage to Behavioral Therapy as Diabetes Guidelines Move GLP-1s Up Front — October 06, 2026
Federal employee health plans will require documented intensive behavioral therapy before and during anti-obesity drug treatment in 2027, while the new ADA-EASD consensus backs GLP-1 or SGLT2 drugs early in type 2 diabetes. Plus a phase 3 oral GLP-1 pill, a new SELECT heart analysis, and what's known about GLP-1s in children.
In this episode
2027 FEHB Changes: Weight Loss Drug Rules, A New FSA Card, And Plans Leaving | FedSmith.com — Ian Smith
# 2027 FEHB Changes: Weight Loss Drug Rules, A New FSA Card, And Plans Leaving | FedSmith.com
Author: Ian Smith
Published: 2026-10-05T16:40:00Z
Source: fedsmith.com
Language: en
## Story
2027 FEHB Changes: Weight Loss Drug Rules, A New FSA Card, And Plans Leaving | FedSmith.com
# 2027 FEHB Changes: Weight Loss Drug Rules, a New FSA Card, and Plans Leaving
From weight loss drug rules to a new…
The 2026 Diabetes Consensus Backs GLP-1 or SGLT2 Drugs Early, Possibly From Diagnosis, Without Waiting on Metformin | Peptide News Digest — Peptide News Digest
The 2026 Diabetes Consensus Backs GLP-1 or SGLT2 Drugs Early, Possibly From Diagnosis, Without Waiting on Metformin | Peptide News Digest
Evidence Brief October 4, 2026 · 7 min read
# The 2026 Diabetes Consensus Backs GLP-1 or SGLT2 Drugs Early, Possibly From Diagnosis, Without Waiting on Metformin
The American Diabetes Association and the European Association for the Study of Diabetes…
Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial | Nature Medicine — Nature Medicine
# Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial | Nature Medicine
Author: Guo, Lixin, Yu, Dongni, Xu, Yimei, Tang, Guo, Peng, Liang
Published: 2026-10-05T10:54:20Z
Source: nature.com
Language: en
## Story
Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a…
Semaglutide heart benefits not fully explained by weight loss - The Pharmacist — Victoria Vaughan
Semaglutide heart benefits not fully explained by weight loss - The Pharmacist
# Semaglutide heart benefits not fully explained by weight loss
By Jerome Smail
5th October 2026
aprott / iStock / Getty Images Plus
The cardiovascular benefits of the GLP-1 receptor agonist semaglutide cannot be fully explained by weight loss or improvements in other known risk factors, according to a new…
Weight loss GLP-1s are everywhere and kids are taking them too. 7 things parents should know – PolitiFact — Madison Czopek
Weight loss GLP-1s are everywhere and kids are taking them too. 7 things parents should know – PolitiFact
# Weight loss GLP-1s are everywhere and kids are taking them too. 7 things parents should know
Doses of Wegovy, a drug used for weight loss, are stored in a refrigerator at Donna Cooper's home in Front Royal, Va., on March 1, 2024. (AP)
By Madison Czopek October 5, 2026
#### If…
Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email [email protected].
11 min
October 05Rhode Island Joins the Medicaid GLP-1 Cutbacks as Massachusetts Weight-Loss Use Falls 52% — October 05, 2026
Rhode Island Medicaid stopped covering GLP-1s prescribed only for weight loss on October 1, and new Massachusetts data shows weight-loss use fell 52% after insurers pulled back. Plus Cigna employees pressing their own employer, a physician's case against the compounding market, and semaglutide's benefits across frailty levels.
In this episode
Rhode Island Medicaid Ends Coverage of Wegovy,… — Inkl
# Rhode Island Medicaid Ends Coverage of Wegovy, Zepbound, and Other GLP-1 Drugs Prescribed Only for Weight Loss
Author: Cole Mercer
Published: 2026-10-03T12:50:36Z
Source: medicaldaily.com
Language: en
## Story
Rhode Island Medicaid Ends Coverage of Wegovy, Zepbound, and Other GLP-1 Drugs Prescribed Only for Weight Loss
Oct 03, 08:50 am EDT
[Medical…
GLP-1 use for weight loss plunges 52% in Massachusetts after insurers cut coverage — Morgan Taylor
Insurers Cut Coverage — GLP‑1 Weight‑Loss Use in Massachusetts Falls 52%, Impacting 112,000 Patients - CRBC News
# Insurers Cut Coverage — GLP‑1 Weight‑Loss Use in Massachusetts Falls 52%, Impacting 112,000 Patients
Morgan Taylor| The Cool Down
Oct 3• 3 min read 2 Save
Massachusetts saw a 52% decline in GLP‑1 use for weight loss between 2025 and Q1 2026 after multiple commercial and state…
OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage — PR Newswire
OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage
# OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage
Obesity Action Coalition
Oct 02, 2026, 08:15 ET
TAMPA, Fla., Oct. 2, 2026 /PRNewswire/ -- The Obesity Action Coalition (OAC) is calling on Cigna to listen to its employees and reconsider its decision to end coverage of GLP-1 medications for weight…
I'm an obesity expert and can't wait for the compounding craze to stop | Fortune — Adonis Saremi
# I'm an obesity expert and can't wait for the compounding craze to stop | Fortune
Author: Adonis Saremi
Published: 2026-10-03T11:30:00Z
Source: fortune.com
Language: en
## Story
I'm an obesity expert and can't wait for the compounding craze to stop | Fortune
# I’m an obesity expert and can’t wait for the compounding craze to stop
By
Adonis Saremi
October 3, 2026, 7:30 AM ET
Dr. Adonis…
Semaglutide Demonstrates Benefits Across Frailty Levels | Obesity | JAMA | JAMA Network — Samantha Anderer
Semaglutide Demonstrates Benefits Across Frailty Levels | Obesity | JAMA | JAMA Network
# Semaglutide Demonstrates Benefits Across Frailty Levels
Samantha Anderer
Article Information
Published Online: October 2, 2026
The glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide demonstrated safety and efficacy regardless of frailty status, a study published in JAMA Cardiology…
Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email [email protected].
11 min
October 02A $75 Copay Cliff for GLP-1 Adherence as New Mexico's Medicaid Ozempic Bill Climbs — October 02, 2026
A JAMA Health Forum study finds GLP-1 nonadherence tops 80% once monthly out-of-pocket costs pass $75, while New Mexico's Medicaid Ozempic spending hit $38.7 million in 2025. Plus survodutide's Phase 3 in NEJM, the amylin tolerability tradeoff, and Novo's injection-to-pill switch data.
In this episode
Higher GLP-1 costs lead to lower adherence | EurekAlert! — EurekAlert!
Higher GLP-1 costs lead to lower adherence | EurekAlert!
News Release 30-Sep-2026
# Higher GLP-1 costs lead to lower adherence
Patients significantly less likely to use the weight loss medication when monthly costs exceed $75
University of Georgia
Semaglutides, or GLP-1s, can produce substantial weight loss if individuals adhere to their doctor’s instructions. But a new study from the…
Ozempic driving massive increase in New Mexico Medicaid prescription drug spending | Local News | santafenewmexican.com — Margaret O'Hara [email protected]
Ozempic driving massive increase in New Mexico Medicaid prescription drug spending | Local News | santafenewmexican.com
# Ozempic driving massive increase in New Mexico Medicaid prescription drug spending
Follow Margaret O'Hara
- By Margaret O'Hara [email protected]
#### Margaret O'Hara
Health Care Accountability Reporter
- Author email ([email protected])
- Sep 29, 2026…
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes - BioSpace — BioSpace
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes - BioSpace
# Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic…
Novel amylin drug confers 10% weight loss, well tolerated — Dorothy Brooks
# Novel amylin drug confers 10% weight loss, well tolerated
Author: Erik Swain
Published: 2026-09-30T00:00:00
Source: healio.com (healio.com)
Language: en
## Story
Novel amylin drug confers 10% weight loss, well tolerated
By Erik Swain
Fact checked by Richard Smith
# Novel amylin drug confers 10% weight loss with adverse events comparable to placebo
September 30, 2026 5 min read
By…
People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026 — Annika Kim Constantino
# People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026
Author: NOVO NORDISK INC.
Published: 2026-09-30T09:45:00+00:00
Source: prnewswire.com (prnewswire.com)
Language: en
## Story
People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on…
Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email [email protected].
10 min
October 01Zepbound Returns to CVS Caremark as Massachusetts Faces Equity Pushback on GLP-1 Cuts — October 01, 2026
Zepbound is back on CVS Caremark's standard commercial formulary starting October 1, but employers still decide, while Massachusetts critics press the state to undo its GLP-1 weight-loss coverage cuts. Plus a JAMA Health Forum Medicaid study on prior authorization, Lilly-sponsored ACHIEVE-4 heart-safety data for Foundayo in The Lancet, and California's new CalRx GLP-1 law.
In this episode
CVS Caremark Adds Zepbound Back October 1, 2026: What to Ask HR Before Open Enrollment — Skinnyvip
CVS Caremark Adds Zepbound Back October 1, 2026: What to Ask HR Before Open Enrollment
# CVS Caremark Adds Zepbound Back October 1, 2026: What to Ask HR Before Open Enrollment
Dr. SkinnyVIP September 15, 2026 ~9 min read
Formulary details current as of September 15, 2026
This guide summarizes CVS Caremark’s May 28, 2026 announcement and standard commercial formulary template as of the…
Critics say GLP-1 coverage shift raises equity issues — The Boston Globe
# Critics say GLP-1 coverage shift raises equity issues
Author: Alison Kuznitz
Published: 2026-09-30T21:56:03.616000+00:00
Source: bostonglobe.com (bostonglobe.com)
Language: en
## Story
Critics say GLP-1 coverage shift raises equity issues
# Critics say GLP-1 coverage shift raises equity issues
A woman holds a Wegovy injector pen in her Wenatchee, Wash., home, on June 3, 2024. M. SCOTT…
Medicaid Coverage of Obesity GLP-1s May Shift From Diabetes Version — Drugtopics
# Medicaid Coverage of Obesity GLP-1s May Shift From Diabetes Version
Published: 2026-09-30T14:00:00+00:00
Source: drugtopics.com (drugtopics.com)
Language: en
## Story
---
## title: "Medicaid Coverage of Obesity GLP-1s May Shift From Diabetes Version"
description: "Medicaid coverage of obesity-labeled GLP-1 receptor agonists may substitute for, rather than simply add to, diabetes-labeled…
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study — EurekAlert!
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
# Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
By PR Newswire | September 30, 2026,…
Newsom signs law allowing California-made GLP-1 drugs — Redding
Newsom signs law allowing California-made GLP-1 drugs
# California’s GLP-1 law could expand access to obesity treatment
Ernesto Centeno Araujo
USA TODAY NETWORK
Sept. 29, 2026, 4:42 p.m. PT
Gov. Gavin Newsom recently signed a law that would allow California to make and distribute a generic version of a popular class of weight-loss drugs through the state's CalRx program.
California…
Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email [email protected].
11 min
September 30Counterfeit Ozempic Indictment Lands as Retatrutide Data Hits EASD — September 30, 2026
Counterfeit Ozempic allegedly sourced from China is at the center of a federal indictment of two Indian nationals in Tampa. At EASD in Milan, Lilly-funded Phase 3 retatrutide results appear in The Lancet, and a Novo-funded registry study finds no semaglutide–pancreatic cancer link.
In this episode
Two Indicted in Florida for International Counterfeit Ozempic Smuggling Scheme | The Front Page — The Front Page
Two Indicted in Florida for International Counterfeit Ozempic Smuggling Scheme | The Front Page
# Two Indicted in Florida for International Counterfeit Ozempic Smuggling Scheme
Swapnadip Roy and Vicky Ramancha were indicted on smuggling and conspiracy charges for distributing counterfeit Ozempic, with Roy appearing in a Florida federal court following his extradition from Italy.
via CBS…
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes — Finviz
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
# Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
By PR Newswire | September 29, 2026, 6:00 PM
In…
Novo, Lilly unleash dueling GLP-1 datasets at EASD in Milan — Fierce Pharma
Novo, Lilly unleash dueling GLP-1 datasets at EASD in Milan
# Novo, Lilly pit their GLP-1s against one another in diabetes and obesity as EASD kicks off in Milan
By Fraiser Kansteiner Sep 29, 2026 11:20am
Finding unique features to pin one’s GLP-1 pitch on has become increasingly important both for developers hoping to catch the next wave of obesity treatments and for Novo’s and Lilly’s…
Regulator-mandated study finds no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway | EurekAlert! — EurekAlert!
Regulator-mandated study finds no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway | EurekAlert!
News Release 28-Sep-2026
# Regulator-mandated study finds no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway
New research to be presented at the Annual Meeting of…
Step Back — With an alleged counterfeit Ozempic smuggling scheme now under investigation, how can patients tell whether a GLP-1 prescription came through a legitimate, FDA-regulated supply chain—and what should they do if the packaging, pharmacy, or product seems suspicious?Background sources
FDA warns consumers not to use counterfeit Ozempic ... — Fda
Office of Public Affairs | Two Indian Nationals Charged in Connection with Transnational Counterfeit Ozempic Scheme | United States Department of Justice — United States Department of Justice
FDA's Concerns with Unapproved GLP-1 Drugs Used for ... — Fda
Compounded GLP-1s: Why doctors worry and the FDA is ... — Stanford
Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email [email protected].
10 min
September 29Zealand, Roche Start Petrelintide Phase 3 as 100% Pharma Tariffs Begin — September 29, 2026
Zealand Pharma and Roche have launched a roughly 7,000-person Phase 3 program for once-weekly petrelintide in obesity. Meanwhile, a baseline 100 percent Section 232 tariff on imported patented medicines and ingredients takes effect and EASD convenes in Milan.
In this episode
Global Registrational Phase 3 ZUPREME Program Evaluating Petrelintide in Overweight or Obesity Initiated – Zealand Pharma - Medical Update Online — Medical Update Online
Global Registrational Phase 3 ZUPREME Program Evaluating Petrelintide in Overweight or Obesity Initiated – Zealand Pharma - Medical Update Online
# Global Registrational Phase 3 ZUPREME Program Evaluating Petrelintide in Overweight or Obesity Initiated – Zealand Pharma
Written by Charlie King | 27 Sep 2026 | Diabetes & Endocrinology
Zealand Pharma A/S announces the initiation of the global…
Navigating Pharma’s Forced Supply Chain Revolution - Chemistry Today — Chemistry Today
Navigating Pharma’s Forced Supply Chain Revolution - Chemistry Today
# Navigating Pharma’s Forced Supply Chain Revolution
by [email protected] 28 September 2026
M. Klote 28 September 2026
Molly Klote, MD President and CEO, Klote Medical Research Advisors, LLC, Washington, DC, United States Former Director, Office for Human Research Protections, US Department of Health and Human…
EASD 2026 to Feature New Diabetes Approaches in T1DM, T2DM, obesity - Dagensdiabetes — Dagens Diabetes
EASD 2026 to Feature New Diabetes Approaches in T1DM, T2DM, obesity - Dagensdiabetes
Senaste Nr DiabetologNytt i PDF
## EASD 2026 to Feature New Diabetes Approaches in T1DM, T2DM, obesity
Key Points • This year’s European Association for the Study of Diabetes (EASD) 2026 Annual Meeting in Milan, Italy, (from September 28 to October 2) will feature new data on first-line treatment approaches…
Republicans and Democrats Find a Unifying Target: Pharmacy Benefit Managers — KFF Health News
Amye Joseph says America’s political polarization has made it an “interesting time” in her Tennessee household. She and her husband, Charlie, have been married 35 years. She’s a Republican. He’s a Democrat. But their shared disenchantment with profit-driven healthcare has provided a unifying target: pharmacy benefit managers, known as PBMs. The Josephs’ frustration is focused on CVS Health. The…
Oral solid dose at a turning point: Scaling for the next generation of therapies - Pharmaceutical Technology — Pharmaceutical Technology
Oral solid dose at a turning point: Scaling for the next generation of therapies - Pharmaceutical Technology
# Oral solid dose at a turning point: Scaling for the next generation of therapies
From patient-centric designs and sustainable changes to component shortages, anti-counterfeiting, and low-volume production, sponsors of oral solid dose pharmaceuticals and their CDMOs are navigating a…
Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email [email protected].
10 min
September 28Mylan Tests Novo's Wegovy Patents as States Target Chinese GLP-1 Supply — September 28, 2026
Mylan is asking a Delaware court to clear its proposed generic Wegovy from a new Novo Nordisk patent. Twenty state attorneys general are warning the White House about Chinese GLP-1 ingredient suppliers, and doctors are flagging a rare vision-loss risk still under study.
In this episode
Mylan asks US court to clear Wegovy generic from Novo patent claims | Reuters — Reuters
Mylan asks US court to clear Wegovy generic from Novo patent claims | Reuters
Skip to main content
Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv
Subscribe
# Mylan asks US court to clear Wegovy generic from Novo patent claims
By Blake Brittain
September 25, 20267:23 PM UTCUpdated ago
Text
*
Small Text
*
Medium Text
*
Large…
Step Back — Mylan is asking a court to clear a Wegovy generic from Novo Nordisk’s patent claims—what would a win actually change for patients, and why wouldn’t it automatically mean a generic could appear immediately?Background sources
Mylan asks US court to clear Wegovy generic from Novo patent claims | Reuters — Blake Brittain
Mylan Wants Del. Judge To Clear Wegovy Generic Drug - Law360 — Law360
Novo Nordisk, Inc. v. Mylan Pharm. Inc. (792 F.Supp.3d 536) - vLex United States — Vlex
Novo, Mylan Jockey Over Trial Timing in Wegovy Patent Dispute — Bloomberglaw
Mylan seeks declaratory judgment against Novo Nordisk over newly issued Wegovy patent, aiming to preempt a new Delaware lawsuit – ip fray — Ipfray
Tennessee AG Skrmetti Joins 20-State Warning over Chinese Weight-Loss Drug Suppliers Linked to Fentanyl Precursors - Tennessee Star — Tennessee Star
Tennessee AG Skrmetti Joins 20-State Warning over Chinese Weight-Loss Drug Suppliers Linked to Fentanyl Precursors - Tennessee Star
# Tennessee AG Skrmetti Joins 20-State Warning over Chinese Weight-Loss Drug Suppliers Linked to Fentanyl Precursors
September 25, 2026 Tom Pappert
Tennessee Attorney General Jonathan Skrmetti announced this week that his office joined 19 other state attorneys…
Doctor warns of 'eye stroke' risk linked to GLP-1 weight loss drugs - Health - News - Daily Express US — Daily Express US
Doctor warns of 'eye stroke' risk linked to GLP-1 weight loss drugs - Health - News - Daily Express US
## Despite the risk, doctors are warning that diabetes and obesity still have proven health risks if gone untreated.
By Cheyenne R. Ubiera
15:11 ET, Sun, Sep 27, 2026 Updated: 15:11 ET, Sun, Sep 27, 2026
Doctors are warning of a rare eye condition linked to GLP-1 drugs (Image: Corbis via…
Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily wherever you listen. Feedback? Email [email protected].
8 min

About GLP-1 Daily: Ozempic & Wegovy News

From the publisher's feed

GLP-1 Daily: Ozempic & Wegovy News is a weekday briefing on GLP-1 drugs for patients and anyone about to start one. In about eight minutes, anchor Cassidy and cohost Silvara cover what changed…

Share GLP-1 Daily: Ozempic & Wegovy News

Sign up to save your podcasts

GLP-1 Daily: Ozempic & Wegovy News

GLP-1 Daily: Ozempic & Wegovy News episodes

About GLP-1 Daily: Ozempic & Wegovy News